Home » Stocks » Cue Biopharma

Cue Biopharma, Inc. (CUE)

Stock Price: $20.75 USD 0.00 (0.00%)
Updated Jul 14, 2020 12:31 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 590.33M
Revenue (ttm) 3.99M
Net Income (ttm) -38.25M
Shares Out 28.43M
EPS (ttm) -1.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 14, 2020
Last Price $20.75
Previous Close $20.75
Change ($) 0.00
Change (%) 0.00%
Day's Open 20.64
Day's Range 20.17 - 21.26
Day's Volume 130,793
52-Week Range 6.54 - 31.69

More Stats

Market Cap 590.33M
Enterprise Value 543.74M
Earnings Date (est) Aug 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 28.43M
Float 19.46M
EPS (basic) -1.61
EPS (diluted) -1.63
FCF / Share -1.25
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.74M
Short Ratio 4.02
Short % of Float 6.32%
Beta 2.18
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 148.02
PB Ratio 14.26
Revenue 3.99M
Operating Income -38.34M
Net Income -38.25M
Free Cash Flow -33.17M
Net Cash 46.59M
Net Cash / Share 1.64
Gross Margin -602.49%
Operating Margin -961.19%
Profit Margin -959.00%
FCF Margin -831.57%
ROA -45.28%
ROE -109.33%
ROIC -225.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 4
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$31.80*
(53.25% upside)
Low
30.0
Current: 20.75
High
34.0
Target: 31.80
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue3.461.14---
Revenue Growth202.67%----
Gross Profit3.461.14---
Operating Income-36.77-38.70-23.23-7.66-1.93
Net Income-36.70-38.98-23.23-7.66-1.93
Shares Outstanding22.0420.1310.737.435.66
Earnings Per Share-1.66-1.94-2.16-1.03-0.34
Operating Cash Flow-30.80-26.41-12.14-5.97-1.66
Capital Expenditures0.08-1.85-1.03-0.52-0.75
Free Cash Flow-30.72-28.27-13.17-6.48-2.41
Cash & Equivalents61.9840.2863.5815.096.55
Total Debt5.80----
Net Cash / Debt56.1940.2863.5815.096.55
Assets71.6145.3666.9516.287.31
Liabilities17.0211.395.351.100.38
Book Value54.5833.9761.6115.176.94
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cue Biopharma, Inc.
Country United States
Employees 45
CEO Daniel R. Passeri

Stock Information

Ticker Symbol CUE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CUE
IPO Date January 2, 2018

Description

Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, an onco-fetal viral antigen for cancers, including solid tumors and hematologic malignancies; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases, as well as a strategic research collaboration with Dr. Michael Dustin and Oxford University. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.